Beryl Drugs Limited (BOM:524606)
India
· Delayed Price · Currency is INR 20.29
-0.83 (-3.93%)
At close: Apr 30, 2025
Beryl Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 201.48 | 267.3 | 268.71 | 146.04 | 140.93 | 128.15 | Upgrade
|
| Other Revenue | 0 | 0 | - | - | - | - | Upgrade
|
| Revenue | 201.48 | 267.3 | 268.71 | 146.04 | 140.93 | 128.15 | Upgrade
|
| Revenue Growth (YoY) | -32.53% | -0.53% | 84.00% | 3.62% | 9.97% | -1.12% | Upgrade
|
| Cost of Revenue | 114.09 | 135.62 | 148.43 | 85.66 | 75.99 | 68.21 | Upgrade
|
| Gross Profit | 87.39 | 131.68 | 120.28 | 60.37 | 64.94 | 59.94 | Upgrade
|
| Selling, General & Admin | 21.4 | 19.61 | 17.3 | 13.46 | 12.08 | 10.04 | Upgrade
|
| Other Operating Expenses | 43.73 | 84.76 | 80.64 | 41.4 | 36.68 | 38.7 | Upgrade
|
| Operating Expenses | 78.43 | 117.24 | 106.18 | 65.72 | 61.49 | 55.34 | Upgrade
|
| Operating Income | 8.96 | 14.44 | 14.1 | -5.35 | 3.45 | 4.6 | Upgrade
|
| Interest Expense | -5.69 | -4.48 | -4.18 | -4.2 | -4.27 | -2.97 | Upgrade
|
| Interest & Investment Income | 0.21 | 0.21 | 0.12 | 0.14 | 0.17 | 0.19 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.18 | -0.18 | -0.2 | 0 | -0.39 | -0.24 | Upgrade
|
| EBT Excluding Unusual Items | 3.3 | 9.99 | 9.84 | -9.41 | -1.04 | 1.58 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.11 | 0.11 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -0.09 | 4.52 | - | Upgrade
|
| Pretax Income | 3.41 | 10.1 | 9.84 | -9.5 | 3.48 | 1.58 | Upgrade
|
| Income Tax Expense | 2.61 | 2.41 | 2.18 | -2.91 | 1.08 | 1.1 | Upgrade
|
| Net Income | 0.8 | 7.69 | 7.66 | -6.59 | 2.4 | 0.48 | Upgrade
|
| Net Income to Common | 0.8 | 7.69 | 7.66 | -6.59 | 2.4 | 0.48 | Upgrade
|
| Net Income Growth | -93.23% | 0.34% | - | - | 399.78% | -91.88% | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | -0.05% | - | - | -0.01% | 0.01% | - | Upgrade
|
| EPS (Basic) | 0.16 | 1.52 | 1.51 | -1.30 | 0.47 | 0.09 | Upgrade
|
| EPS (Diluted) | 0.16 | 1.52 | 1.51 | -1.30 | 0.47 | 0.09 | Upgrade
|
| EPS Growth | -93.23% | 0.36% | - | - | 422.22% | -92.24% | Upgrade
|
| Free Cash Flow | - | -5.31 | 8.28 | -8.84 | -13.33 | -16.9 | Upgrade
|
| Free Cash Flow Per Share | - | -1.05 | 1.63 | -1.74 | -2.63 | -3.33 | Upgrade
|
| Gross Margin | 43.38% | 49.26% | 44.76% | 41.34% | 46.08% | 46.78% | Upgrade
|
| Operating Margin | 4.45% | 5.40% | 5.25% | -3.66% | 2.45% | 3.59% | Upgrade
|
| Profit Margin | 0.40% | 2.88% | 2.85% | -4.51% | 1.70% | 0.37% | Upgrade
|
| Free Cash Flow Margin | - | -1.99% | 3.08% | -6.05% | -9.46% | -13.19% | Upgrade
|
| EBITDA | 23.86 | 26.44 | 22.25 | 5.52 | 16.18 | 11.2 | Upgrade
|
| EBITDA Margin | 11.84% | 9.89% | 8.28% | 3.78% | 11.48% | 8.74% | Upgrade
|
| D&A For EBITDA | 14.9 | 12 | 8.14 | 10.87 | 12.74 | 6.59 | Upgrade
|
| EBIT | 8.96 | 14.44 | 14.1 | -5.35 | 3.45 | 4.6 | Upgrade
|
| EBIT Margin | 4.45% | 5.40% | 5.25% | -3.66% | 2.45% | 3.59% | Upgrade
|
| Effective Tax Rate | 76.59% | 23.87% | 22.14% | - | 31.15% | 69.64% | Upgrade
|
| Revenue as Reported | 205.44 | 271.25 | 271.4 | 147.69 | 142.8 | 130.48 | Upgrade
|
| Advertising Expenses | - | 0.12 | 0.17 | 0.13 | 0.13 | 0.25 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.